Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Michael C Nivens"'
Autor:
Gil Yosipovitch, MD, Brian S. Kim, MD, Shawn G. Kwatra, MD, Nicholas K. Mollanazar, MD, Sonja Ständer, MD, Takahiro Satoh, MD, PhD, Pedro Mendes-Bastos, MD, Tsen-Fang Tsai, MD, Elizabeth Laws, PhD, Michael C. Nivens, PhD, Jennifer Maloney, MD, Genming Shi, PhD, Ashish Bansal, MD, MBA, Ariane Dubost-Brama, MD
Publikováno v:
JAAD International, Vol 16, Iss , Pp 163-174 (2024)
Background: Phase 3 PRIME/PRIME2 trials independently demonstrated efficacy and an acceptable safety profile of dupilumab adults with moderate-to-severe prurigo nodularis. Objective: To obtain a more precise estimate of onset and magnitude of treatme
Externí odkaz:
https://doaj.org/article/711afba8cadd4d1c95210d2031b7c4d3
Autor:
Klaus F. Rabe, Fernando J. Martinez, Surya P. Bhatt, Tomotaka Kawayama, Borja G. Cosio, Robert M. Mroz, Maarten M. Boomsma, Helene Goulaouic, Michael C. Nivens, Michel Djandji, Xavier Soler, Ying Liu, Matthew P. Kosloski, Christine R. Xu, Nikhil Amin, Heribert Staudinger, David J. Lederer, Raolat M. Abdulai
Publikováno v:
ERJ Open Research, Vol 10, Iss 5 (2024)
Background Accumulating data implicate interleukin (IL)-33, a proinflammatory cytokine released locally upon epithelial cell damage, in the pathogenesis of COPD. In a phase 2 study, itepekimab, a human monoclonal antibody against IL-33, reduced exace
Externí odkaz:
https://doaj.org/article/3bd4edef6ab44bf1a5e1e7bec238bd0c
Autor:
Matthew P. Kosloski, Emma Guttman‐Yassky, Michael J. Cork, Margitta Worm, Dong‐Ho Nahm, Xiaoping Zhu, Marcella K. Ruddy, Sivan Harel, Mohamed A. Kamal, Hélène Goulaouic, Christine R. Xu, Elena Avetisova, John D. Davis, Michael C. Nivens, Arsalan Shabbir, Allen Radin
Publikováno v:
Clinical and Translational Science, Vol 17, Iss 8, Pp n/a-n/a (2024)
Abstract Interleukin‐33 (IL‐33) is a proinflammatory alarmin cytokine released by damaged epithelial tissue cells that initiates and amplifies both type 1 and type 2 inflammatory cascades. A role for IL‐33 in atopic dermatitis (AD; a chronic, r
Externí odkaz:
https://doaj.org/article/574d478bee6847e5989bba493bdec8fc
Autor:
Wolfgang A. Schmidt, Bhaskar Dasgupta, Jennifer Sloane, Angeliki Giannelou, Yuqing Xu, Sebastian H. Unizony, Sarah L. Mackie, Miguel A. Gonzalez-Gay, Robert Spiera, Kenneth J. Warrington, Peter M. Villiger, Michael C. Nivens, Bolanle Akinlade, Yong Lin, Frank Buttgereit, John H. Stone
Publikováno v:
Arthritis Research & Therapy, Vol 25, Iss 1, Pp 1-16 (2023)
Abstract Background Giant cell arteritis (GCA) is primarily treated with glucocorticoids (GCs), which have substantial toxicity. Tocilizumab, an interleukin-6-receptor inhibitor (IL-6Ri), showed beneficial effects in GCA, leading to its approval. Thi
Externí odkaz:
https://doaj.org/article/4519641ec60d4627b6d5c6d36c1bb6ac
Autor:
Pavel Kovalenko, Anne Paccaly, Anita Boyapati, Christine Xu, Gregory St John, Michael C. Nivens, John D. Davis, Ronda Rippley, A. Thomas DiCioccio
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 9, Iss 7, Pp 405-414 (2020)
Evidence suggests that effects of interleukin‐6 pathway inhibitors sarilumab, tocilizumab, and sirukumab on absolute neutrophil count (ANC) are due to margination of circulating neutrophils into rapidly mobilizable noncirculating pools. We develope
Externí odkaz:
https://doaj.org/article/67c9b10110704a98b5052e51a5d05f23
Autor:
Nan Lin, Amy Damask, Anita Boyapati, Jennifer D. Hamilton, Sara Hamon, Nils Ternes, Michael C. Nivens, John Penn, Alexander Lopez, Jeffrey G. Reid, John Overton, Alan R. Shuldiner, Goncalo Abecasis, Aris Baras, Charles Paulding
Publikováno v:
The Pharmacogenomics Journal. 22:160-165
Sarilumab is a human monoclonal antibody against interleukin (IL)-6Rα that has been approved for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) and an inadequate response or intolerance to one or more di
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d61fa204c8862547a651af46bed3c9fb
https://doi.org/10.1038/s41397-022-00269-5
https://doi.org/10.1038/s41397-022-00269-5
Autor:
Helene Goulaouic, Michael E. Wechsler, Andreas Jessel, George D. Yancopoulos, Elliot Israel, Ian D. Pavord, Jorge Maspero, Nikhil Amin, Linda B. Ford, Klaus F. Rabe, Marcella Ruddy, Michael C Nivens, David M. Weinreich, Chih-Chi Hu, Renata Martincova, Raolat M Abdulai
Publikováno v:
New England Journal of Medicine. 385:1656-1668
Monoclonal antibodies targeting IgE, interleukin-4 and -13, and interleukin-5 are effective in treating severe type 2 asthma, but new targets are needed. Itepekimab is a new monoclonal antibody against the upstream alarmin interleukin-33. The efficac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ead5dcc2e92090216c860a90da7e8062
https://doi.org/10.1056/nejmoa2024257
https://doi.org/10.1056/nejmoa2024257
Autor:
John J Flanagan, Giane Sumner, Alpana Waldron, Matthew F. Wipperman, Rafia Bhore, Sara Hamon, Peter J. Ehmann, D.J. Lederer, Jennifer D. Hamilton, Michael C Nivens, Sumathi Sivapalasingam, Anita Boyapati, Elif Kabuloglu Karayusuf
Publikováno v:
The Journal of Infectious Diseases
Background Elucidating the relationship between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load and clinical outcomes is critical for understanding coronavirus disease 2019 (COVID-19). Methods The SARS-CoV-2 levels were analyz
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05e041845596acc7f833d2629c10c377
https://doi.org/10.1093/infdis/jiab445
https://doi.org/10.1093/infdis/jiab445
Autor:
Tomonori Ishii, Qiang Lu, Christine Xu, Vanaja Kanamaluru, Ernest Choy, Jeanette L. Fairhurst, Anne Paccaly, Terra Potocky, Melitza Iglesias-Rodriguez, Patrick Nolain, Gregory St John, Michael C Nivens, Rafael Maldonado, Paul Emery, Ashique Rafique
Publikováno v:
The Journal of Clinical Pharmacology. 61:714-724
We evaluated interleukin-6 (IL-6) receptor-α subunit (IL-6Rα) signaling inhibition with sarilumab and tocilizumab, the association between IL-6Rα receptor occupancy (RO) and C-reactive protein (CRP), and the potential clinical relevance of any dif
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4aae5d4b8faa94a2b9c0d020bfc9ebdf
https://doi.org/10.1002/jcph.1795
https://doi.org/10.1002/jcph.1795
Autor:
A. Thomas DiCioccio, John D. Davis, Anita Boyapati, Michael C Nivens, Pavel Kovalenko, Ronda Rippley, Anne Paccaly, Gregory St John, Christine Xu
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 9, Iss 7, Pp 405-414 (2020)
CPT: Pharmacometrics & Systems Pharmacology
CPT: Pharmacometrics & Systems Pharmacology
Evidence suggests that effects of interleukin-6 pathway inhibitors sarilumab, tocilizumab, and sirukumab on absolute neutrophil count (ANC) are due to margination of circulating neutrophils into rapidly mobilizable noncirculating pools. We developed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::450896787db30bbee39d6c677debb7d7
https://doaj.org/article/67c9b10110704a98b5052e51a5d05f23
https://doaj.org/article/67c9b10110704a98b5052e51a5d05f23